Skip to main content
    N

    NRX Pharmaceuticals Inc (NRXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.71
    +0.12 (+4.63%)

    Market Cap: $112.14M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    47%(8/17)
    Avg Surprise
    -145.02%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.08-87.5%
    60d ago$-0.08-87.5%
    30d ago$-0.08-87.5%
    7d ago$-0.08-87.5%
    Current$-0.15
    Revenue Consensus
    $1M
    Range$1M - $2M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.41
    Range$-0.41 - $-0.41
    1 analysts
    Revenue Consensus
    $-22571920
    Range$-23881670 - $-19981670
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.41---
    Sep 26EST
    		-$-0.15---
    Jun 26
    Reported Aug 14
    		$-0.18$-0.09-100.00%Miss+81.6%
    Mar 26
    Reported May 15
    		$-0.04N/A+63.64%Beat+88.2%
    Dec 25
    Reported Mar 23
    		$0.18$-0.08+329.13%Beat+123.8%
    Sep 25
    Reported Nov 14
    		$-0.51$-0.02-2450.00%Miss-240.0%
    Jun 25
    Reported Aug 18
    		$-0.98$-0.23-326.09%Miss-30.7%
    Mar 25
    Reported May 15
    		$-0.34$-0.53+35.85%Beat+54.1%
    Dec 24
    Reported Mar 14
    		$-0.77$-0.37-108.11%Miss-54.0%
    Sep 24
    Reported Nov 14
    		$-0.15N/A+77.27%Beat+78.6%
    Jun 24
    Reported Aug 14
    		$-0.75$-0.69-8.70%Miss+37.5%
    Mar 24
    Reported May 14
    		$-0.74$-0.55-34.55%Miss-362.5%
    Dec 23
    Reported Mar 29
    		$-0.50$-0.80+37.50%Beat+68.8%
    Sep 23
    Reported Nov 13
    		$-0.70$-1.15+39.13%Beat+50.0%
    Jun 23
    Reported Aug 14
    		$-1.20$-1.40+14.29%Beat-9.1%
    Mar 23
    Reported May 16
    		$-0.16$-0.14-14.29%Miss+23.8%
    Dec 22
    Reported Mar 30
    		$-1.60$-1.45-10.34%Miss-201.9%
    Sep 22
    Reported Nov 14
    		$-1.40$-1.40+0.00%Beat-250.0%
    Jun 22
    Reported Aug 15
    		$-1.10$-1.00-10.00%Miss+83.1%
    Mar 22
    Reported May 16
    		$-0.21N/AN/ABeat-31.2%
    Dec 21
    Reported Mar 31
    		$-0.53N/AN/ABeat+76.5%
    Sep 21
    Reported Nov 16
    		$-0.40N/AN/ABeat-700.0%
    Jun 21
    Reported Aug 16
    		$-6.51$0.00N/AMiss-10750.0%
    Mar 21
    Reported Apr 1
    		$-0.16N/AN/ABeat-260.0%
    Dec 20
    Reported Mar 31
    		$-2.26N/AN/ABeat-22488.0%
    Sep 20
    Reported Nov 16
    		$-0.05N/AN/ABeat-600.0%
    Jun 20
    Reported Aug 14
    		$-0.06N/AN/ABeat-300.0%
    Mar 20
    Reported May 15
    		$0.10N/AN/ABeat+400.0%
    Dec 19
    Reported Mar 30
    		$-0.01N/AN/ABeat-131.1%
    Sep 19
    Reported Nov 14
    		$0.01N/AN/ABeat-67.8%
    Jun 19
    Reported Aug 14
    		$0.03N/AN/ABeat+511.0%
    Mar 19
    Reported May 15
    		$0.02N/AN/ABeat+16.3%
    Dec 18
    Reported Mar 15
    		$0.03N/AN/ABeat+125.9%
    Sep 18
    Reported Nov 8
    		$0.03N/AN/ABeat-
    Jun 18
    Reported Aug 8
    		$-0.01N/AN/ABeat-
    Mar 18
    Reported May 15
    		$0.02N/AN/ABeat-
    Dec 17
    Reported Mar 23
    		$-0.12N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-4.96EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-590.00%
    ROE-683.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.86xQuick Ratio0.86x
    Trading Statistics
    Beta2.07Avg Volume653.31K
    52-Week High$5.0552-Week Low$1.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.82
    SMA 20$2.94
    SMA 50$3.24
    SMA 200$2.96
    EMA 10$2.80
    EMA 20$2.93
    EMA 50$3.18
    EMA 200$3.11

    MACD

    Line: -0.17Signal: -0.15Hist: -0.01

    ADX

    ADX: 26.1+DI: 10.6-DI: 31.0

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down100.0
    PSAR$2.87

    Bollinger Bands

    Upper Band$3.34
    Lower Band$2.55
    %B Position2688%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    33.9

    Momentum Oscillators

    Stoch %K16.9
    Stoch %D11.3
    Williams %R-60.3
    ROC (10d)-4.9%
    Momentum-0.14
    CCI (20d)-131.8
    MFI (14d)41.8

    Volatility Measures

    ATR (14d)$0.16(5.9%)
    StdDev (20d)0.20
    Hist Vol41.7%(High)

    Volume Flow

    VWAP$2.65
    OBV32.3M
    AD Line7.5M
    CMF (20d)-0.253

    Volume Metrics

    Avg Vol (20d)643.4K
    Vol Ratio1.8x(High)
    VWMA (20d)$2.93

    Pivot Points

    R3$2.82
    R2$2.76
    R1$2.68
    Pivot Point$2.62
    S1$2.53
    S2$2.47
    S3$2.39

    Advanced Oscillators

    TSI-34.54
    Ultimate Osc45.7
    KST-161.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.10M$1.07M$983,000$242,000$0$4,000$4,000$0$0$8,000$8,000$0
    Cost of Revenue$843,000$796,000$508,000$138,000$0$2,000$1,000$2,000$1,000$1,000$1,000$2,000
    Gross Profit$258,000$272,000$475,000$104,000$0$2,000$-1,000$-2,000$-1,000$-1,000$-1,000$-2,000
    Operating Expenses$6.76M$5.02M$5.07M$4.22M$3.73M$3.85M$3.63M$3.02M$7.05M$6.00M$4.41M$5.81M
    R&D$2.12M$1.31M$558,000$1.43M$987,000$804,000$1.04M$611,000$2.80M$1.75M$2.53M$3.31M
    SG&A$4.75M$3.81M$4.57M$2.81M$2.74M$2.94M$2.60M$2.41M$4.25M$4.25M$1.87M$2.49M
    Operating Income$-6,505,000$-4,748,000$-4,594,000$-4,118,000$-3,730,000$-3,847,000$-3,634,000$-3,022,000$-7,050,000$-5,998,000$-4,406,000$-5,808,000
    Interest Income$6,000$5,000$4,000$2,000$2,000$4,000$4,000$6,000$7,000$27,000$74,000$119,000
    Interest Expense$240,000$233,000$671,000$0$0$0$0$0$849,000$230,000$80,000$40,000
    Income Before Tax$-16,520,000$-1,430,000$360,000$-5,890,000$-17,581,000$-5,512,000$-9,078,000$-1,623,000$-7,897,000$-6,528,000$-4,332,000$-6,062,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$-42,276$-1,394,000$40,000
    Net Income$-16,520,000$-1,430,000$360,000$-5,890,000$-17,581,000$-5,512,000$-9,078,000$-1,623,000$-7,897,000$-6,528,000$-4,332,000$-6,062,000
    EBITDA$-16,107,000$-1,032,000$1.13M$-5,847,000$-17,581,000$-5,511,000$-9,077,000$-1,621,000$-7,047,000$-6,297,000$-4,251,000$-6,020,000
    EBIT$-16,280,000$-1,197,000$1.03M$-5,890,000$-3,730,000$-5,512,000$-9,078,000$-1,623,000$-7,048,000$-6,298,000$-4,252,000$-6,022,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NRXP

    News

    NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

    NRx Pharmaceuticals announced that it received a "DISCIPLINE REVIEW LETTER" from the FDA requesting "MINOR" changes to the submitted label for its Preservative-Free Ketamine product. The company needs to submit sample...

    GlobeNewswire•10/15/26•Bullish

    FDA asks NRx to send labels showing the proposed name for its preservative-free ketamine

    NRx Pharmaceuticals (NRXP) announced that the FDA has requested minor changes to the submitted label for its preservative-free ketamine product. The FDA also asked NRx to submit sample labeling with the proposed...

    Stock Titan•10/15/26•Somewhat-Bullish

    NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024

    NRx Pharmaceuticals, Inc. announced its participation in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. Dr. Jonathan Javitt, Chairman and Chief Scientist...

    Lelezard•10/8/26•Somewhat-Bullish

    NRx Pharmaceuticals Lands DARPA Contract for SPARC-TMS Trial

    NRx Pharmaceuticals' subsidiary, NRx Defense Systems, secured an $11.2 million DARPA contract to conduct the SPARC-TMS clinical trial for treatment-resistant depression. This FDA-approved trial...

    The Globe and Mail•10/7/26•Bullish

    NRx Pharmaceuticals Lands DARPA Contract for SPARC-TMS Trial

    NRx Pharmaceuticals' subsidiary, NRx Defense Systems, secured an $11.2 million DARPA contract for the SPARC-TMS clinical trial in treatment-resistant depression. The trial will evaluate a single-day robotic transcranial...

    The Globe and Mail•10/7/26•Somewhat-Bullish

    NRXP Valuation and Fair Value

    P/E
    -5.0x
    Forward P/E
    34.3x
    P/B
    -600.2x
    See GNG's fair value

    NRXP Profitability: Margins, ROIC and FCF

    Gross margin
    32.7%
    Operating margin
    -590.0%
    Net margin
    0.0%
    ROE
    -683.0%
    FCF margin
    -609.0%

    NRXP Competitors

    CompanyTicker
    TuHURA Biosciences IncHURA
    vTv Therapeutics IncVTVT
    Minerva Neurosciences IncNERV
    Cellectis SACLLS
    Cumberland Pharmaceuticals IncCPIX
    Foghorn Therapeutics IncFHTX
    Repare Therapeutics IncRPTX
    Tonix Pharmaceuticals Holding CorpTNXP

    Sector: Healthcare

    NRXP Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    NRXP Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -309.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About NRXP

    Does NRXP pay dividends?

    NRX Pharmaceuticals Inc (NRXP) does not currently pay a regular dividend.

    What is NRXP's market cap?

    NRX Pharmaceuticals Inc (NRXP) has a market capitalization of $112.14M with a current stock price of $2.71.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In